stockrow
Wednesday 11 November 2026
Export REPL’s income statement to Excel — free account
Replimune Group, Inc.
REPL- EPS
- +39.7%
- Free cash flow
- +42.2%
- Total debt
- +74.3%
Quarter to September 2026, against a year earlier
21.88
1.40
−6.01%
Follow REPL
Alert me
Replimune Group, Inc. (REPL) Gross margin
Replimune Group, Inc.'s gross margin over the twelve months to 30 September 2023 was 0.00%, down 0.0 percentage points from fiscal 2023 (0.00%). Over the past ten years it has ranged from 0.00% (fiscal 2023) to 0.00% (fiscal 2023) — the current reading is the highest in ten years. That is below the Biotechnology industry median of 68.8% and below the Healthcare sector median of 55.5%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2023 | 0.00% | 0.00 |
| Jun 2023 | 0.00% | 0.00 |
| Mar 2023 | 0.00% | 0.00 |
| Dec 2022 | 0.00% | 0.00 |
| 12 more quarters | Free account |
Against its own ten years
Low 0.00%
High 0.00%
Ten-year median
0.00%
Current reading's percentile
100
Gross margin against peers
| Company | Gross margin |
|---|---|
| IMNM Immunome, Inc. compare | 100.0% |
| VIR Vir Biotechnology, Inc. compare | 100.0% |
| AUPH Aurinia Pharmaceuticals Inc compare | 90.6% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 89.8% |
| ZYME Zymeworks Inc. compare | 51.4% |
| RXRX Recursion Pharmaceuticals, Inc. compare | 29.2% |
| VERA Vera Therapeutics, Inc. compare | 0.00% |
| REPL Replimune Group, Inc. | 0.00% |
| TRAX First Tracks Biotherapeutics, Inc. compare | — |
| Biotechnology industry median | 68.8% |
| Healthcare sector median | 55.5% |
| Market median | 47.0% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue